Figure 2.

Serum irisin levels are decreased in hepatocellular carcinoma (HCC) patients. (a) Serum irisin levels in healthy controls and HCC patients. Serum irisin levels were measured by ELISA in healthy controls (Control, n = 102) and hepatocellular carcinoma patients (HCC, n = 117). Data were presented as the mean ± SD. Differences between the groups were compared by Student's t-test. (b) A receiver operating characteristic (ROC) curve of serum irisin to distinguish HCC patients from healthy controls.